These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 8615645

  • 1. Alterations of vinblastine influx in multidrug-resistant lymphoblastic leukaemic CEM cells.
    Colin M, Madoulet C, Warren L, Jardillier JC.
    Anticancer Res; 1996; 16(1):407-12. PubMed ID: 8615645
    [Abstract] [Full Text] [Related]

  • 2. Study of sodium orthovanadate as a reverser of multidrug resistance on lymphoblastic leukemic CEM/VLB100 cells.
    Colin M, Madoulet C, Baccard N, Arsac F, Jardillier JC.
    Anticancer Res; 1994; 14(6A):2383-7. PubMed ID: 7825977
    [Abstract] [Full Text] [Related]

  • 3. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts.
    Beck WT, Cirtain MC, Lefko JL.
    Mol Pharmacol; 1983 Nov; 24(3):485-92. PubMed ID: 6579344
    [Abstract] [Full Text] [Related]

  • 4. Secretion of lysosomal enzymes by drug-sensitive and multiple drug-resistant cells.
    Warren L, Jardillier JC, Ordentlich P.
    Cancer Res; 1991 Apr 15; 51(8):1996-2001. PubMed ID: 1672622
    [Abstract] [Full Text] [Related]

  • 5. Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.
    Hill AB, Beck WT, Trent JM.
    Cancer Res; 1988 Jan 15; 48(2):393-8. PubMed ID: 2891436
    [Abstract] [Full Text] [Related]

  • 6. Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype.
    Mi Q, Cui B, Silva GL, Lantvit D, Lim E, Chai H, You M, Hollingshead MG, Mayo JG, Kinghorn AD, Pezzuto JM.
    Cancer Res; 2001 May 15; 61(10):4030-7. PubMed ID: 11358822
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
    Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP, Trent JM.
    Cancer Res; 1987 Oct 15; 47(20):5455-60. PubMed ID: 2888532
    [Abstract] [Full Text] [Related]

  • 8. Continued expression of vinca alkaloid resistance by CCRF-CEM cells after treatment with tunicamycin or pronase.
    Beck WT, Cirtain MC.
    Cancer Res; 1982 Jan 15; 42(1):184-9. PubMed ID: 7198507
    [Abstract] [Full Text] [Related]

  • 9. A flow cell assay for evaluation of whole cell drug efflux kinetics: analysis of paclitaxel efflux in CCRF-CEM leukemia cells overexpressing P-glycoprotein.
    Lin JT, Sharma R, Grady JJ, Awasthi S.
    Drug Metab Dispos; 2001 Feb 15; 29(2):103-10. PubMed ID: 11159798
    [Abstract] [Full Text] [Related]

  • 10. Increased accumulation of drugs in multidrug-resistant cells induced by liposomes.
    Warren L, Jardillier JC, Malarska A, Akeli MG.
    Cancer Res; 1992 Jun 01; 52(11):3241-5. PubMed ID: 1591733
    [Abstract] [Full Text] [Related]

  • 11. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
    Beck WT, Cirtain MC, Look AT, Ashmun RA.
    Cancer Res; 1986 Feb 01; 46(2):778-84. PubMed ID: 3455678
    [Abstract] [Full Text] [Related]

  • 12. Reversal of P-glycoprotein-mediated multidrug resistance by cholesterol derived from low density lipoprotein in a vinblastine-resistant human lymphoblastic leukemia cell line.
    Shu Y, Liu H.
    Biochem Cell Biol; 2007 Oct 01; 85(5):638-46. PubMed ID: 17901905
    [Abstract] [Full Text] [Related]

  • 13. Vinblastine transport by membrane vesicles from human multidrug-resistant CCRF-CEM leukaemia cells: inhibition by taxol and membrane permeabilising agents.
    Syed SK, Christopherson RI, Roufogalis BD.
    Biochem Mol Biol Int; 1993 Jul 01; 30(4):743-53. PubMed ID: 8104621
    [Abstract] [Full Text] [Related]

  • 14. Evidence for reduced drug influx in multidrug resistant CEM cells by a fluorescent dye.
    Colin M, Madoulet C, Robichon H, Kaplan H, Jardillier J.
    Int J Oncol; 1997 Aug 01; 11(2):377-82. PubMed ID: 21528225
    [Abstract] [Full Text] [Related]

  • 15. Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines.
    Hu XF, Martin TJ, Bell DR, de Luise M, Zalcberg JR.
    Cancer Res; 1990 May 15; 50(10):2953-7. PubMed ID: 2334897
    [Abstract] [Full Text] [Related]

  • 16. Characterization of 2-chloro-N10-substituted phenoxazines for reversing multidrug resistance in cancer cells.
    Thimmaiah KN, Jayashree BS, Germain GS, Houghton PJ, Horton JK.
    Oncol Res; 1998 May 15; 10(1):29-41. PubMed ID: 9613455
    [Abstract] [Full Text] [Related]

  • 17. Sanguinarine overcomes P-glycoprotein-mediated multidrug-resistance via induction of apoptosis and oncosis in CEM-VLB 1000 cells.
    Weerasinghe P, Hallock S, Tang SC, Trump B, Liepins A.
    Exp Toxicol Pathol; 2006 Aug 15; 58(1):21-30. PubMed ID: 16735106
    [Abstract] [Full Text] [Related]

  • 18. Characterization of tropane alkaloid aromatic esters that reverse the multidrug-resistance phenotype.
    Mi Q, Cui B, Chávez D, Chai H, Zhu H, Cordell GA, Hedayat S, Kinghorn AD, Pezzuto JM.
    Anticancer Res; 2002 Aug 15; 22(3):1385-97. PubMed ID: 12168815
    [Abstract] [Full Text] [Related]

  • 19. Selective modulation of P-glycoprotein-mediated drug resistance.
    Bebawy M, Morris MB, Roufogalis BD.
    Br J Cancer; 2001 Dec 14; 85(12):1998-2003. PubMed ID: 11747345
    [Abstract] [Full Text] [Related]

  • 20. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H, Genne P, Kadhim S, Bibeau L, Duchamp O, Ouellet F, deMuys JM, Bouffard DY, Attardo G.
    Cancer Chemother Pharmacol; 2002 Dec 14; 50(6):490-6. PubMed ID: 12451476
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.